Exane BNP Paribas is launching a corporate survey on stock price and liquidity as part of market discussions at European level to improve the liquidity of listed companies post Covid-19.
This questionnaire is also an opportunity to express your wishes in terms of liquidity and market transparency. Your responses will be processed anonymously.
We plan to publish the results of our study in November. 
 

Question Title

* 1. Since the onset of the Covid-19 health crisis, excluding March 2020, how have the liquidity / volumes of transactions on your stock evolved?

Question Title

* 2. Since the onset of the Covid-19 health crisis, excluding March 2020, how has the volatility of your stock evolved?

Question Title

* 3. Do you have a good understanding of your stock price drivers?

Question Title

* 4. Do you consider that the information you have on the following elements is sufficient?

Question Title

* 5. What information on your stock price/volumes/flows do you have on a regular basis?

Question Title

* 6. How do you think the liquidity of your stock is rated by investors?

Question Title

* 7. Have any investors mentioned in the last 6 months that stock liquidity is a drag on investment?

Question Title

* 8. How do you judge the liquidity of your stock?

Question Title

* 9. Is your stock liquidity a matter of concern to your Board / Executive Committee?

Question Title

* 10. What is your first statutory threshold?

Question Title

* 11. If you had a request about your listing to make to regulators, what would it be?

Question Title

* 12. Have you implemented a mechanism to improve the liquidity of your stock on the stock market?

0 of 19 answered
 

T